A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
Conditions: Hormone Receptor Positive Breast Carcinoma; HER2-negative Breast Cancer Intervention: Drug: OP-1250 Sponsor: Olema Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | HER2 | Oral Cancer | Research | Study